~ Buy the STRIVERDI RESPIMAT (olodaterol hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

STRIVERDI RESPIMAT Drug Patent Profile

✉ Email this page to a colleague

When do Striverdi Respimat patents expire, and what generic alternatives are available?

Striverdi Respimat is a drug marketed by Boehringer Ingelheim and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and ninety-four patent family members in forty countries.

The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. One supplier is listed for this compound. Additional details are available on the olodaterol hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Striverdi Respimat

Striverdi Respimat was eligible for patent challenges on July 31, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 19, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Try a Trial

Summary for STRIVERDI RESPIMAT

International Patents:	194
US Patents:	9
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	36
Clinical Trials:	2
Patent Applications:	48
Drug Prices:	Drug price information for STRIVERDI RESPIMAT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for STRIVERDI RESPIMAT
What excipients (inactive ingredients) are in STRIVERDI RESPIMAT?	STRIVERDI RESPIMAT excipients list
DailyMed Link:	STRIVERDI RESPIMAT at DailyMed

Drug patent expirations by year for STRIVERDI RESPIMAT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for STRIVERDI RESPIMAT

Generic Entry Date for STRIVERDI RESPIMAT^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: ⤷ Try a Trial NDA: 203108 Dosage: SPRAY, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for STRIVERDI RESPIMAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Università degli Studi di Ferrara	Phase 4
Boehringer Ingelheim

See all STRIVERDI RESPIMAT clinical trials

Pharmacology for STRIVERDI RESPIMAT

Drug Class	beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists

Anatomical Therapeutic Chemical (ATC) Classes for STRIVERDI RESPIMAT

R03AC	Selective beta-2-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

US Patents and Regulatory Information for STRIVERDI RESPIMAT

STRIVERDI RESPIMAT is protected by nine US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of STRIVERDI RESPIMAT is ⤷ Try a Trial.

This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting STRIVERDI RESPIMAT

Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA

Piston-pumping system having o-ring seal properties
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA

Medicaments for the treatment of chronic obstructive pulmonary disease
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Device for clamping a fluidic component
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Microstructured high pressure nozzle with built-in filter function
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Device for clamping a fluidic component
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for STRIVERDI RESPIMAT

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	⤷ Try a Trial	⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	⤷ Try a Trial	⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	⤷ Try a Trial	⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	⤷ Try a Trial	⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	⤷ Try a Trial	⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	⤷ Try a Trial	⤷ Try a Trial
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for STRIVERDI RESPIMAT

See the table below for patents covering STRIVERDI RESPIMAT around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
European Patent Office	1243299	Filtre a microstructure (Microstructured filter)	⤷ Try a Trial
Slovakia	282587		⤷ Try a Trial
Slovakia	12082001	KARTUŠA NA KVAPALINU, UVOĽNITEĽNÉ SPOJENIE MEDZI KARTUŠOU A PRIPOJOVACÍM DIELOM ODOBERACIEHO PRÍSTROJA, NASÚVATEĽNÝ SPODNÝ DIEL PRÍSTROJA, A JEJ POUŽITIE (CARTRIDGE FOR A LIQUID)	⤷ Try a Trial
Germany	59608851		⤷ Try a Trial
Brazil	9611140		⤷ Try a Trial
Hong Kong	1015304		⤷ Try a Trial
Denmark	1611958		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for STRIVERDI RESPIMAT

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1562603	513	Finland	⤷ Try a Trial
1562603	C300650	Netherlands	⤷ Try a Trial	PRODUCT NAME: OLODATEROL, OPTISCHE ISOPMEREN; NAT. REGISTRATION NO/DATE: RVG 112058 20131023; FIRST REGISTRATION:
1562603	122014000018	Germany	⤷ Try a Trial	PRODUCT NAME: OLODATEROL, OPTISCHE ISOMERE DAVON, MISCHUNGEN VON ISOMEREN DAVON, SAEUREADDITIONSSALZE DAVON MIT PHARMAKOLOGISCH UNBEDENKLICHEN SAEUREN, SOWIE SOLVATE UND/ODER HYDRATE DAVON, INSBESONDERE OLODATEROL UND OLODATEROLHYDROCHLORID; NAT. REGISTRATION NO/DATE: 87146.00.00 20131126; FIRST REGISTRATION: MALTA MA 211/00401 20130918
1562603	1490016-1	Sweden	⤷ Try a Trial	PRODUCT NAME: OLODATEROL, INDIVIDUELLA OPTISKA ISOMERER DAERAV, BLANDNINGAR AV DE SEPARATA ENANTIOMERERNA ELLER RACEMATEN DAERAV, SYRA ADDITIONSSALTER DAERAV MED FARMAKOLOGISKT GODTAGBARA SYROR SAVAEL SOM SOLVATER OCH/ELLER HYDRATER DAERAV, SAERSKILT OLODATEROL OCH OLODATEROLHYDROKLORID; NAT. REG. NO/DATE: MT-NR 48116 20131114; FIRST REG.: MT MA 211/00401 20130918
1562603	C01562603/01	Switzerland	⤷ Try a Trial	PRODUCT NAME: OLODATEROL; REGISTRATION NO/DATE: SWISSMEDIC 62880 12.05.2014
1562603	14C0049	France	⤷ Try a Trial	PRODUCT NAME: OLODATEROL, SES ISOMERES OPTIQUES INDIVIDUELS, MELANGES D'ENANTIOMERES INDIVIDUELS OU RACEMATE, SES SELS D'ADDITION D'ACIDE AVEC DES ACIDES PHARMACOLOGIQUEMENT ACCEPTABLES, AINSI QUE DES SOLVATES ET OU HYDRATES, EN PARTICULIER OLODATEROL OU CHLORHYDRATE D'OLODATEROL; NAT. REGISTRATION NO/DATE: NL42395 20140522; FIRST REGISTRATION: MT - MA211/00401 20130918
1562603	159 5009-2014	Slovakia	⤷ Try a Trial	PRODUCT NAME: OLODATEROL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 14/0394/13-S 20131029; FIRST REGISTRATION: MT MA211/00401 20130918
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description